



SVMRFE based approach for prediction of most discriminatory gene target for type II diabetes

Atul Kumar^{a,*}, D. Jeya Sundara Sharmila^b, Sachidanand Singh^a

^a Department of Biotechnology and Health Sciences, Karunya University, Coimbatore, Tamil Nadu, India

^b Department of Nanosciences and Technology, Tamil Nadu Agriculture University, Coimbatore, Tamil Nadu, India

ARTICLE INFO

Article history:

Received 29 November 2016

Received in revised form 7 February 2017

Accepted 15 February 2017

Available online 17 February 2017

Keywords:

Type II diabetes

SVMRFE

Microarray

Protein-protein interaction

t-test

ABSTRACT

Type II diabetes is a chronic condition that affects the way our body metabolizes sugar. The body's important source of fuel is now becoming a chronic disease all over the world. It is now very necessary to identify the new potential targets for the drugs which not only control the disease but also can treat it. Support vector machines are the classifier which has a potential to make a classification of the discriminatory genes and non-discriminatory genes. SVMRFE a modification of SVM ranks the genes based on their discriminatory power and eliminate the genes which are not involved in causing the disease. A gene regulatory network has been formed with the top ranked coding genes to identify their role in causing diabetes. To further validate the results pathway study was performed to identify the involvement of the coding genes in type II diabetes. The genes obtained from this study showed a significant involvement in causing the disease, which may be used as a potential drug target.

© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Support Vector Machine (SVM), a machine learning technique implied in the area of time series prediction and classification [31,36] has widely been applied in the life science fields, especially in Bioinformatics. It can handle nonlinear classification tasks efficiently by mapping the samples into a higher dimensional feature space by using a nonlinear kernel function. Since the SVM approach is data-driven and model-free, it has important discriminating power for classification. This characteristic of SVM is obvious in cases where the sample sizes are negligible and numerous variables are involved (high-dimensional space).

Expression profile come under such a category, which contain a large number of attributes (genes). This type of expression data is used to predict the type and occurrence of the disease in a patient [39]. An important aspect while analyzing such type of expression data is the feature selection or dimensionality reduction. Most algorithms lose their potency when genes are large in number with different time series data or dimensionality [7].

To accomplish the task of dimensionality reduction a modified version of SVM known as SVMRFE (Support Vector Machine Recursive Feature Elimination) has been used in this work. SVMRFE was used to identify the most discriminatory target gene in four different microarray

data samples of type II diabetes. These samples have been taken from the Gene Expression Omnibus database (GEO) [13] and Diabetes Genome Anatomy Project (DGAP) (<http://www.diabetesgenome.org/>). The idea was to build a model wherein the least important features (genes) can be eliminated at each iterative step based on the weight assigned to each gene through SVM. The genes identified through this approach were then classified as essential and non-essential genes. The protein-protein interaction of these non-essential genes revealed vital information regarding interacting proteins. Functional enrichment about these proteins shed a light on their regulatory pathways associated with type II diabetes which can be further explored and confirmed using experimental approach.

2. Materials and methods

2.1. Collection of data sample

71 samples from Pancreatic Islet and Skeletal muscle of *Homo sapiens* were collected from the GEO and DGAP. Out of these 37 samples are of normal human beings and 34 are of diabetic humans. Table 1 shows the detail description of each of the data sets which were undertaken for studies.

Fisher linear discriminant was applied to all the above-mentioned data sets to rank them based on the Fischer score [21] which was continued with a redundancy reduction step to reduce the redundant data in the microarray dataset [22]. The gene number present in each data set

* Corresponding author.

E-mail address: atulkumar@karunya.edu (A. Kumar).

Table 1
Microarray dataset undertaken for studies.

Source	Data	No. of samples		No. of genes	Country
		Normal	Diabetic		
GEO	Effect of insulin infusion on human skeletal muscle [33]	6	6	22,215	Sweden
DGAP	Human pancreatic islets from normal and Type 2 diabetic subjects (A) [18]	7	5	22,191	Caucasian and Asian
DGAP	Human pancreatic islets from normal and Type 2 diabetic subjects (B) [18]	7	5	22,550	
DGAP	Human skeletal muscle - type 2 diabetes [29]	17	18	22,177	Sweden




Fig. 1. Flow chart of the analysis.

was still high. A *t*-test [3] with a significance level of 0.05 was applied to the datasets to filter out the genes which are not involved in causing type II diabetes. After this reduction step SVMRFE approach (with linear kernel function and 6 subsets of the training data) [24] was applied to train the data samples for 5 iterations. As a result, discriminatory genes based on the weighted ranking were obtained. The identified genes were identified as being essential and non-essential using the database of essential genes. A gene interaction and pathway analysis of the potential non-essential genes was performed to identify the novel targets for type II diabetes (Fig. 1)

3. Result and discussion

3.1. *t*-test analysis

For each of the T2D datasets, a *t*-test analysis was performed with a significance level of 0.05. As a result, there was a high dimensionality

Table 2
Number of input and output genes from each dataset for *t*-test analysis.

Name of dataset	No of inputted genes	No of genes rejecting the null hypothesis
Effect of insulin infusion on human skeletal muscle	1223	24
Human pancreatic islets from normal and type II diabetic subjects (A)	1210	17
Human pancreatic islets from normal and type II diabetic subjects (B)	803	21
Human skeletal muscle-type II diabetes	1238	28

Table 3
p-value of genes following the alternative hypothesis for the dataset "GSE7146".

Probe id	Gene	p-Value
213524_s_at	G0/G1switch 2	0.00001
216599_x_at	Solute carrier family 22 (organic anion transporter), member 6	0.00005
207295_at	Sodium channel, non-voltage-gated 1, gamma	0.0001
218409_s_at	DnaJ (Hsp40) homolog, subfamily C, member 1	0.0003
203221_at	Transducin-like enhancer of split 1 (E (sp1) homolog, <i>Drosophila</i>)	0.0004
210452_x_at	Cytochrome P450, family 4, subfamily F, polypeptide 2	0.001
201630_s_at	Acid phosphatase 1, soluble	0.001
207955_at	Chemokine (C-C motif) ligand 27	0.002
208507_at	Olfactory receptor, family 7, subfamily C, member 2	0.002
210889_s_at	Fc fragment of IgG, low affinity IIb, receptor (CD32)	0.002
207732_s_at	Discs, large homolog 3 (neuroendocrine-dlg, <i>Drosophila</i>)	0.002
220636_at	Dynein, axonemal, intermediate polypeptide 2	0.002
205863_at	S100 calcium binding protein A12	0.002
205603_s_at	Diaphanous homolog 2 (<i>Drosophila</i>)	0.003
220979_s_at	ST6 (alpha-N-acetyl-neuraminy 1-2, 3-beta-galactosy 1-1, 3) -N-acetylgalactosaminide alpha-2, 6-sialyltransferase 5	0.003
206310_at	Serine peptidase inhibitor, Kazal Type II (acrosin-trypsin inhibitor)	0.004
210442_at	Interleukin 1 receptor-like 1	0.004
201214_s_at	Protein phosphatase 1, regulatory subunit 7	0.004
220385_at	Junctophilin 2	0.004
205490_x_at	Gap junction protein, beta 3, 31 kDa (connexin 31)	0.004
213772_s_at	Golgi-associated, gamma adaptin ear containing, ARF binding protein 2	0.004
213950_s_at	Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma)	0.004
201681_s_at	Discs, large homolog 5 (<i>Drosophila</i>)	0.004
220782_x_at	Kallikrein-related peptidase 12	0.004

Table 4

p-Value of genes following the alternative hypothesis for the dataset “human pancreatic islets from normal and type II diabetic subjects (A)”.

Probe id	Gene	p-Value
207406_at	Cytochrome P450, family 7, subfamily A, polypeptide 1	0.0003
214046_at	Fucosyltransferase 9 (alpha (1,3) fucosyltransferase)	0.0004
213980_s_at	C-terminal binding protein 1	0.0005
202854_at	Hypoxanthine phosphoribosyltransferase 1	0.0005
215300_s_at	Flavin containing monooxygenase 5	0.0007
212894_at	Suppressor of var1, 3-like 1 (<i>S. cerevisiae</i>)	0.0012
202605_at	Glucuronidase, beta	0.0017
203196_at	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	0.0021
205633_s_at	Aminolevulinate, delta-, synthase 1	0.0022
207673_at	Nephrosis 1, congenital, Finnish type (nephrin)	0.0027
209759_s_at	Enoyl-CoA delta isomerase 1	0.003
208926_at	Sialidase 1 (lysosomal sialidase)	0.003
205627_at	Cytidine deaminase	0.004
210284_s_at	TGF-beta activated kinase 1/MAP3K7 binding protein 2	0.004
213931_at	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	0.0043
213426_s_at	Caveolin 2	0.0047
221572_s_at	Solute carrier family 26, member 6	0.0049

reduction in each dataset (Table 2). The genes rejecting the null hypothesis were obtained for each of the data samples. Tables 3–6 show the corresponding p-values of all the genes which have rejected the null hypothesis at significance level of 0.05. The Figs. 2–5 represent graphically the p-value of all the genes in the four datasets under consideration. The p-value for most of the genes was above the significance level value of 0.05. This represents that these genes have almost the same expression value in the normal and diseased and may not be involved in causing the disease.

3.2. Identification of best-ranked genes from SVMRFE

The subsets of genes based on the p-value were given as an input to the support vector machine. Recursive Feature Elimination (RFE) is an

Table 5

p-Value of genes following the alternative hypothesis for the dataset “human pancreatic islets from normal and type II diabetic subjects (B)”.

Probe id	Gene	p-Value
227787_s_at	Thyroid hormone receptor-associated protein 6	0.0001
222478_at	Vacuolar protein sorting 36 (yeast)	0.0002
230329_s_at	Nudix (nucleoside diphosphate linked moiety X) -type motif 6	0.0003
226424_at	Calcyphosine	0.0003
225491_at	Solute carrier family 1 (glial high affinity glutamate transporter), member 2	0.0004
225016_at	Adenomatosis polyposis coli down-regulated 1	0.0005
243043_at	RAD50 interactor 1	0.0008
224573_at	Ribonuclease, RNase K	0.0012
228133_s_at	Myosin, heavy polypeptide 11, smooth muscle	0.0013
225108_at	Alkylglycerone phosphate synthase	0.0013
224865_at	Male sterility domain containing 2	0.0024
231880_at	Family with sequence similarity 40, member B	0.0026
241739_at	2-oxoglutarate and iron-dependent oxygenase domain containing 1	0.003
228036_s_at	F-box protein 2	0.0031
223978_s_at	Cardiolipin synthase 1	0.0032
244706_at	Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1	0.0033
237718_at	Eukaryotic translation initiation factor 4E	0.0033
222999_s_at	Cyclin L2	0.0038
230318_at	Serpin peptidase inhibitor, clade A (alpha-1 antitrypsin), member 1	0.0039
222408_s_at	Yippee-like 5 (<i>Drosophila</i>)	0.004
224954_at	Serine hydroxymethyltransferase 1 (soluble)	0.0046

Table 6

p-Value of genes following the alternative hypothesis for the dataset “human skeletal muscle-type II diabetes”.

Probe id	Gene	p-Value
219572_at	Ca++-dependent secretion activator 2	0.0002
204447_at	Leucine zipper, putative tumor suppressor family member 3	0.0002
221410_x_at	Protocadherin beta 3	0.0003
201764_at	Transmembrane protein 106C	0.0005
201429_s_at	Ribosomal protein L37a	0.0008
204761_at	USP6 N-terminal like	0.001
219642_s_at	Peroxisomal biogenesis factor 5-like	0.001
218592_s_at	Cat eye syndrome chromosome region, candidate 5	0.001
210835_s_at	C-terminal binding protein 2	0.001
216695_s_at	Tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase	0.001
208067_x_at	Ubiquitously transcribed tetratricopeptide repeat containing, Y-linked	0.001
209400_at	Solute carrier family 12 (potassium/chloride transporters), member 4	0.001
201262_s_at	Biglycan	0.001
203171_s_at	Ribosomal RNA processing 8, methyltransferase, homolog (yeast)	0.002
207131_x_at	Gamma-glutamyltransferase 1	0.002
219464_at	Carbonic anhydrase XIV	0.002
206345_s_at	Paraoxonase 1	0.002
210907_s_at	Programmed cell death 10	0.002
202641_at	ADP-ribosylation factor-like 3	0.002
204969_s_at	Radixin	0.003
222289_at	Potassium voltage-gated channel, Shaw-related subfamily, member 2	0.003
210318_at	Retinol binding protein 3, interstitial	0.003
219301_s_at	Contactin associated protein-like 2	0.004
203116_s_at	Ferrochelatase	0.004
207242_s_at	Glutamate receptor, ionotropic, kainate 1	0.004
214005_at	Gamma-glutamyl carboxylase	0.004
215529_x_at	DIP2 disco-interacting protein 2 homolog A (<i>Drosophila</i>)	0.004

iterative procedure for SVM classifier. The recursive feature elimination algorithm of the support vector machine assigns a weight to each gene. The weight was calculated based on the expression value of genes in the disease and the normal sample for all the dataset. The algorithm classified the genes (with a classification accuracy of 83.9%) based on the descending order of the weight. Then it generated the list of genes which were found to be the most discriminatory in the normal and disease samples (Tables 7–10). The outline for SVMRFE in the linear kernel is presented below:

Inputs:

Training samples

$$X_0 = [x_1, x_2, \dots, x_n]^T$$

Class labels (1 for normal or 0 for diseased)

$$y = [y_1, y_2, \dots, y_n]^T$$

Initialize:

Surviving genes

$$s = [1, 2, \dots, n]$$

Gene-ranking list

$$r = []$$

Limit training samples to good genes

$$X = x_0(:, s)$$

Train the classifier

$$\alpha = \text{SVM-train}(X, y)$$

Compute the weight from each selected gene:

$$w = \sum_k \alpha_k y_k x_k \text{ where } k \text{ indicates the } k^{\text{th}} \text{ training pattern}$$

Compute the ranking criterion for the i^{th} gene

$$R(i) = (w_i) [2]$$

Mark the gene with the lowest ranking

$$g = \arg \min (R)$$

Renew the gene-ranking list

$$r = [s(g), r]$$




Fig. 2. p-Value corresponding to all the genes in the training set for dataset “GSE7146”.

Eliminate the gene with the lowest ranking

$s = s(1:g - 1, g + 1:\text{length}(s))$

Repeat until $s = []$

Output:

A gene-ranking list r

3.3. Identification of degree of essentiality and non-essentiality of genes

To identify significant and reliable targets, the work was concentrated on non-essential genes. Essential genes were ruled out based on the hits obtained from the Database of Essential Genes (DEG 10.9) (<http://tubic.tju.edu.cn/deg/>) [46]. Essential genes sustain an organism. Therefore, having them as a potential gene target may induce side effects of the drugs. Hence, it is important to identify only the non-essential genes which may be used as a potential drug target. Tables 11–14 show the non-essential genes from the microarray dataset which is under study

3.4. Gene interaction studies

After obtaining the non-essential genes from the top ranked coding genes for each of the datasets, gene regulatory network was constructed using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database [40]. The study was mainly done to observe the interaction between non-essential protein-coding genes with other proteins which are a result of biochemical events and/or electrostatic forces [23]. The function and activity of a protein are often modulated by other proteins with which it interacts.

3.4.1. Gene regulatory network of dataset “GSE7146”

In this dataset, out of the ten best coding genes obtained through the SVMRF approach, only 5 genes (ACP1, FCGR2B, SCNN1G, CCL27, and DLG3) showed interaction with other protein coding genes (Fig. 6). The ACP1 showed a direct interaction with EPHA2, which is reported to increase the chance of myocardial infarction and reduce the survival




Fig. 3. p-Value corresponding to all the genes in the training set for dataset “human pancreatic islets from normal and type II diabetic subjects (A)”.




Fig. 4. p-Value corresponding to all the genes in the training set for dataset “human pancreatic islets from normal and type II diabetic subjects (B)”.

rate of hyperglycemic mice [12]. LYN showed indirect interaction with ACP1 via EPHA2 and direct interaction with FCGR2B. Its kinase activation modulation has been reported to be a novel insulin receptor-potentiating agent. This potentiating agent produces a rapid-onset and a durable blood glucose-lowering activity in diabetic animals [32]. FCGR2B also showed direct interaction with PTPN6 which is been reported to negatively regulate insulin action on glucose homeostasis in the liver and muscle [44]. An analysis of DLG3 has shown its direct interaction with GRIN2A and GRIN2B. Both these genes have been reported to play a potential role in diabetes [11,37,42]. UBC has been reported to play a major role in the diabetes pathway [8,16,26] and its direct interaction with SCNN1G shows that SCNN1G may also play a role in diabetes pathway. CCL27 interacts with CCL25, a protein whose expression was shown to decrease significantly in diabetes [30].

3.4.2. Gene regulatory network of dataset “human pancreatic islets from normal and type II diabetic subjects (A)”

Except for ABCC4 and FMO5, all the other four proteins showed a significant and strong interaction with other neighboring proteins (Fig. 7).

Purine Nucleoside Phosphorylase (PNP) and Nucleoside Phosphate Kinase (NPK) have reportedly played a major role in diabetes either by positive or negative metabolic regulation [9]. These two molecules also showed interaction with the HPRT1 and the CDA. Caveolin has already been reported to mediate insulin signaling thereby affecting the glucose uptake [6]. In the other subgroup network FUT3 has three direct neighbors: FUT1, FUT2, and B4GALT1 of which the B4GALT1 expression level has been shown to be affected by hyperglycemia [25].

3.4.3. Gene regulatory network of the dataset “human pancreatic islets from normal and type II diabetic subjects (B)”

Both the protein coding genes in this dataset (RNASEK and APCDD1) have shown a significant interaction with the neighboring proteins (Fig. 8). The involvement of RNASEK in diabetes is still an unanswered question, but APCDD1 interaction with its neighbors shows that it may be involved in the pathophysiology of diabetes. LPAR6 (Lysophosphatidic Acid Receptor 6) interacting directly with APCDD1 has shown its activity with PPAR γ which is a potential target for diabetes [38]. Aranda et al., in 2012 also showed that the DM/HG (*Diabetes mellitus/High Glucose*)




Fig. 5. p-Value corresponding to all the genes in the training set for dataset “human skeletal muscle-type II diabetes”.

Table 7

Best ranked genes for dataset “GSE7146”.

Gene name
G0/G1switch 2
Transducin-like enhancer of split 1 (E (sp1) homolog, <i>Drosophila</i>)
Acid phosphatase 1, soluble
DnaJ (Hsp40) homolog, subfamily C, member 1
Golgi-associated, gamma adaptin ear containing, ARF binding protein 2
Protein phosphatase 1, regulatory subunit 7
Interleukin 1 receptor-like 1
Discs, large homolog 5 (<i>Drosophila</i>)
Cytochrome P450, family 4, subfamily F, polypeptide 2
Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma)
Gap junction protein, beta 3, 31 kDa (connexin 31)
Diaphanous homolog 2 (<i>Drosophila</i>)
Olfactory receptor, family 7, subfamily C, member 2
Solute carrier family 22 (organic anion transporter), member 6
Serine peptidase inhibitor, Kazal Type II (acrosin-trypsin inhibitor)
Chemokine (C-C motif) ligand 27
Dynein, axonemal, intermediate chain 2
Junctophilin 2
Kallikrein-related peptidase 12
S100 calcium binding protein A12
Discs, large homolog 3 (neuroendocrine-dlg, <i>Drosophila</i>)
Sodium channel, non-voltage-gated 1, gamma subunit
ST6 (alpha-N-acetyl-neuraminyl-2, 3-beta-galactosyl-1, 3)
-N- acetylglactosaminide alpha-2, 6-sialyltransferase 5
Fc fragment of IgG, low affinity IIb, receptor (CD32)

reprograms signaling pathways in RECs (Retinal Endothelial Cells) to induce a state of LPA (Lysophosphatidic Acid) resistance. In the year 2000, Figueroa et al. [14] showed that alterations in LRP5 expression may be responsible for diabetes susceptibility. Therefore it may be a potential target for therapeutic intervention. It has been reported that Wnt/LRP5 (lipoprotein receptor-related protein 5) signaling contributes to the glucose-induced insulin secretion in the islets [15].

3.4.4. Gene regulatory network of dataset “human skeletal muscle-type II diabetes”

The two prominent protein coding genes (USP6NL and ProSAPiP1) as per SVMRFE analysis showed interaction with a different set of genes (Fig. 9). This selective network of ProSAPiP1 has not been reported till now, for diabetes. The three genes (SOS1, EGFR, and EGF) in the interaction network of USP6NL have shown its significance in connection with diabetes. SOS1 has shown its association with reference to the insulin action [4], in differential expression of EGFR which is a

Table 8

Best ranked genes for dataset “human pancreatic islets from normal and type II diabetic subjects (A)”.

Gene name
Glucuronidase, beta
Enoyl-CoA delta isomerase 1
C-terminal binding protein 1
Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Hypoxanthine phosphoribosyltransferase 1
Sialidase 1 (lysosomal sialidase)
ATP-binding cassette, sub-family C (CFTR/MRP), member 4
Aminolevulinatase, delta-, synthase 1
Suppressor of var1, 3-like 1 (<i>S. cerevisiae</i>)
Flavin-containing monooxygenase 5
Solute carrier family 26, member 6
TGF-beta activated kinase 1/MAP3K7 binding protein 2
Caveolin 2
Nephrosis 1, congenital, Finnish type (nephro)
Fucosyltransferase 9 (alpha (1,3) fucosyltransferase)
Cytidine deaminase
Cytochrome P450, family 7, subfamily A, polypeptide 1

Table 9

Best ranked genes for dataset “human pancreatic islets from normal and type II diabetic subjects (B)”.

Gene name
Adenomatosis polyposis coli down-regulated 1
Ribonuclease, RNase K

Table 10

Best ranked genes for dataset “human skeletal muscle-type II diabetes”.

Gene name
Protocadherin beta 3
Leucine zipper, putative tumor suppressor family member 3
USP6 N-terminal like
Ubiquitously transcribed tetratricopeptide repeat containing, Y-linked

major impact on diabetes and associated diseases [1,5,27,28,41,45]. Kasayama et al. [19] long back in 1989 reported that EGF deficiency occurs in *diabetes mellitus* hence insulin may be important in maintaining the normal level of EGF in the submandibular gland and plasma.

3.5. Functional enrichment of significant genes implying pathway analysis

To further validate the involvement of the identified genes in type II diabetes, pathway enrichment was considered. This was solely meant for all the interacting proteins with the identified significant protein(s). The study was carried out using BioInterpreter, a web-based biological interpretation tool for Microarray data analysis (Genotypic Technology Pvt. Ltd., Bangalore, India). The pathway analysis showed that some of the interacting proteins were involved in pathways which were directly or indirectly associated with type II diabetes.

3.5.1. Pathway enrichment for the interacting proteins of the dataset “effect of insulin infusion on human skeletal muscle”

GRIN2A (Glutamate [NMDA] receptor subunit epsilon-1) and GRIN2B (Glutamate [NMDA] receptor subunit epsilon-2), the two

Table 11

Non-essential genes for dataset “GSE7146”.

Gene symbol	Gene name
G0S2	G0/G1switch 2
ACP1	Acid phosphatase 1, soluble
CCL27	Chemokine (C-C motif) ligand 27
JPH2	Junctophilin 2
KLK12	Kallikrein-related peptidase 12
S100A12	S100 calcium binding protein A12
DLG3	Discs, large homolog 3 (neuroendocrine-dlg, <i>Drosophila</i>)
SCNN1G	Sodium channel, non-voltage-gated 1, gamma subunit
ST6GALNAC5	ST6 (alpha-N-acetyl-neuraminyl-2, 3-beta-galactosyl-1, 3)
	-N-acetylglactosaminide alpha-2, 6-sialyltransferase 5
FCGR2B	Fc fragment of IgG, low-affinity IIb, receptor (CD32)

Table 12

Non-essential genes for dataset “human pancreatic islets from normal and type II diabetic subjects (A)”.

Gene symbol	Gene name
HPRT1	Hypoxanthine phosphoribosyltransferase 1
ABCC4	ATP-binding cassette, sub-family C (CFTR/MRP), member 4
FMO5	Flavin-containing monooxygenase 5
CAV2	Caveolin 2
FUT3	Fucosyltransferase 9 (alpha (1, 3) fucosyltransferase)
CDA	Cytidine deaminase

Table 13
Non-essential genes for dataset “human pancreatic islets from normal and type II diabetic subjects (B)”.

Gene symbol	Gene name
APCDD1	Adenomatosis polyposis coli down-regulated 1
RNASEK	Ribonuclease, RNase K

Table 14
Non-essential genes for dataset “human skeletal muscle-type II diabetes”.

Gene symbol	Gene name
USP6NL	Leucine zipper, putative tumor suppressor family member 3
PROSAP1P1	USP6 N-terminal like

proteins interacting mainly with the identified protein DLG3 have been shown to be involved in 3 different pathways viz. Neuroactive ligand-receptor interaction, circadian entrainment and Long-term potentiation (Fig. 10). The proteins present in the Neuroactive ligand-receptor interaction have shown a significant role in the pathobiology of obesity and type II diabetes [10]. The second pathway, circadian entrainment is the biological process that displays an endogenous oscillation of about 24 h. Studies show that exposure to light at night lowers glucose-stimulated insulin secretion due to a decrease in insulin secretory pulse mass. Potential mechanisms have been identified by which disturbances in the circadian rhythms due to modern lifestyle can lead to islet failure in the type II diabetes [35]. It has also been reported that the impaired energy utilization from insulin deficiency impairs a long-term potentiation in diabetes [47].




Fig. 6. Gene regulatory network of dataset “GSE7146”.




Fig. 7. Gene regulatory network of dataset “human pancreatic islets from normal and type II diabetic subjects (A)”.




Fig. 8. Gene regulatory network of dataset “human pancreatic islets from normal and type II diabetic subjects (B)”.

3.5.2. Pathway enrichment for the interacting proteins of the dataset “human pancreatic islets from normal and type II diabetic subjects (A)”

The protein B4GALT1, interacting with the identified protein FUT3 is involved in several metabolic pathways, connected to type II diabetes (Fig. 11). The protein B4GALT1 participates both in glycoconjugate and lactose biosynthesis. It has shown to be a biomarker in hepatocellular carcinoma, mainly caused due to the insulin resistance syndrome. Finally, the ailment manifests as obesity and later as diabetes [17].

3.5.3. Pathway enrichment for the interacting proteins of the dataset “human pancreatic islets from normal and type II diabetic subjects (B)”

The protein PNPT1 interacting with the RNASEK is reported to be involved in pyrimidine and purine metabolism and the RNA degradation (Fig. 12). Effects of the insulin regulation of purine and pyrimidine

metabolism had shown to cause some late complications of the diabetic disease [34]. In 2009, Kocic et al. [20] reported that an impaired dsRNA metabolism may lead to increased levels of different sized RNAs in type II diabetic patients and may have an influence on further ineffective response against the different pathogens.

3.5.4. Pathway enrichment for the interacting proteins of dataset “human skeletal muscle-type II diabetes”

EGFR protein interacting with the identified protein USP6NL has already been reported by many researchers to be involved in diabetes [1, 5,27,28,41,45]. With the pathway studies, it was identified that the main pathways in which EGFR is involved, is also leading directly to or indirectly to diabetes (Fig. 13). Hypoxia-inducible factor 1 alpha (HIF-1 α) is regulated precisely by hypoxia and hyperglycemia. It had also been




Fig. 9. Gene regulatory network of dataset “human skeletal muscle-type II diabetes”.




Fig. 10. Involvement of GRIN2A and GRIN2B in different pathways.




Fig. 13. Involvement of EGFR in different pathways.




Fig. 11. Involvement of B4GALT1 in different pathways

shown that the HIF-1 α and glucose can sometimes influence each other [43]. It has been reported that the components of the MAPK/ERK pathway act as modifiers of the cellular insulin responsiveness. The insulin resistance was due to downregulation of the insulin-like receptor gene expression following persistent MAPK/ERK inhibition. The mechanism




Fig. 12. Involvement of PNPT1 in different pathways.

permits physiological adjustment of insulin sensitivity and the subsequent maintenance of the circulating glucose at appropriate levels [48]. MAPK and GnRh-Glp-1 pathways in the ileum have also been reported to be involved in the improvement of the blood glucose level [45].

4. Conclusion

Analysis of type II diabetes expression data from two different tissue samples i.e. skeletal muscle and pancreatic islet has given a deep insight into genes which may be possibly involved in the pathophysiology of the disease. The most discriminatory genes obtained in each dataset after complete analysis, have been found to be associated with diabetes either directly or indirectly. However, the majority of the genes have not been previously reported in association with diabetes. The genes identified in the current study viz. *FCGR2B*, *DLG3*, *SCNN1G*, *FUT3*, *HPRT1*, *APCDD1*, *USP6NL*, *ProSAP1P1* and *RNASEK* may act as a potential drug target. The significant pathways identified through the overall approach were Neuroactive ligand-receptor interaction, circadian entrainment, Long-term potentiation, pyrimidine and purine metabolism, dsRNA metabolism, MAPK/ERK pathway, and GnRh-Glp-1. This study gave the insight to focus on these associated pathways with the above-reported proteins to study in pathway models or mouse model to elucidate them as drug targets or markers for type II diabetes.

Conflict of interest

The authors declare that there is no conflict of interest in the present work.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.gdata.2017.02.008>.

References

- [1] A. Advani, K.J. Wiggins, A.J. Cox, Y. Zhang, R.E. Gilbert, D.J. Kelly, Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. *Nephrology* 16 (6) (2011 Aug 1) 573–581.
- [2] J. Aranda, R. Motiejunaite, E. Im, A. Kazlauskas, Diabetes disrupts the response of retinal endothelial cells to the angiomodulator lysophosphatidic acid. *Diabetes* 61 (5) (2012 May 1) 1225–1233.
- [3] P. Baldi, A.D. Long, A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. *Bioinformatics* 17 (6) (2001 Jun 1) 509–519.

- [4] I. Barroso, J.A. Luan, R.P. Middelberg, A.H. Harding, P.W. Franks, R.W. Jakes, D. Clayton, A.J. Schafer, S. O'Rahilly, N.J. Wareham, Candidate gene association study in type 2 diabetes indicates a role for genes involved in β -cell function as well as insulin action. *PLoS Biol.* 1 (1) (2003 Oct 13), e20.
- [5] S. Belmadani, D.I. Palen, R.A. Gonzalez-Villalobos, H.A. Boulares, K. Matrougui, Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. *Diabetes* 57 (2008) 1629–1637.
- [6] A.W. Cohen, T.P. Combs, P.E. Scherer, M.P. Lisanti, Role of caveolin and caveolae in insulin signaling and diabetes. *Am. J. Physiol. Endocrinol. Metab.* 285 (6) (2003 Dec 1) E1151–E1160.
- [7] F. Cordero, M. Botta, R.A. Calogero, Microarray data analysis and mining approaches. *Brief. Funct. Genomic. Proteomic.* 6 (4) (2007 Dec 1) 265–281.
- [8] S. Costes, C.J. Huang, T. Gurlo, M. Daval, A.V. Matveyenko, R.A. Rizza, A.E. Butler, P.C. Butler, β -cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency. *Diabetes* 60 (1) (2011 Jan 1) 227–238.
- [9] P.A. Craven, R.K. Studer, F.R. DeRubertis, Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. *J. Clin. Invest.* 93 (1) (1994 Jan) 311.
- [10] U.N. Das, A.A. Rao, Gene expression profile in obesity and type 2 diabetes mellitus. *Lipids Health Dis.* 6 (1) (2007 Dec 14) 1.
- [11] A.M. Davalli, C. Perego, F.B. Folli, The potential role of glutamate in the current diabetes epidemic. *Acta Diabetol.* 49 (3) (2012 Jun 1) 167–183.
- [12] A. DuSablón, S. Kent, A. Coburn, J. Virag, EphA2-receptor deficiency exacerbates myocardial infarction and reduces survival in hyperglycemic mice. *Cardiovasc. Diabetol.* 13 (1) (2014 Aug 13) 1.
- [13] R. Edgar, M. Domrachev, A.E. Lash, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* 30 (1) (2002 Jan 1) 207–210.
- [14] D.J. Figueroa, J.F. Hess, B. Ky, S.D. Brown, V. Sandig, A. Hermanowski-Vosatka, R.C. Twells, J.A. Todd, C.P. Austin, Expression of the type I diabetes-associated gene LRP5 in macrophages, vitamin A system cells, and the islets of Langerhans suggests multiple potential roles in diabetes. *J. Histochem. Cytochem.* 48 (10) (2000 Oct 1) 1357–1368.
- [15] T. Fujino, H. Asaba, M.J. Kang, Y. Ikeda, H. Sone, S. Takada, D.H. Kim, R.X. Ioka, M. Ono, H. Tomoyori, M. Okubo, Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. *Proc. Natl. Acad. Sci.* 100 (1) (2003 Jan 7) 229–234.
- [16] C. Gao, W. Huang, K. Kanasaki, Y. Xu, The role of ubiquitination and sumoylation in diabetic nephropathy. *Biomed. Res. Int.* (2014 Jun 4) 2014.
- [17] R. Guerrero-Preston, M. Kim, A. Blanco, C. LeBron, R. Santella, M. Berdasco, M. Fraga, M. Esteller, D. Sidransky, B4GALT1 as a potential epigenetic marker of metabolic disruptions associated with Non-Alcoholic Fatty Liver Disease. *Cancer Res.* 68 (9 Supplement) (2008 May 1) (3827–).
- [18] J.E. Gunton, R.N. Kulkarni, S. Yim, T. Okada, W.J. Hawthorne, Y.H. Tseng, R.S. Roberson, C. Ricordi, P.J. O'Connell, F.J. Gonzalez, C.R. Kahn, Loss of ARNT/HIF1 β mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. *Cell* 122 (3) (2005 Aug 12) 337–349.
- [19] S. Kasayama, Y. Ohba, T. Oka, Epidermal growth factor deficiency associated with diabetes mellitus. *Proc. Natl. Acad. Sci.* 86 (19) (1989 Oct 1) 7644–7648.
- [20] G.M. Kocic, R. Kocic, R. Pavlovic, T. Jevtovic-Stoimenov, D. Sokolovic, G. Nikolic, V. Pavlovic, S. Stojanovic, J. Basic, A. Veljkovic, D. Pavlovic, Possible impact of impaired double-stranded RNA degradation and nitrosative stress on immuno-inflammatory cascade in type 2 diabetes. *Exp. Clin. Endocrinol. Diabetes* 117 (09) (2009 Oct) 480–485.
- [21] A. Kumar, D.J. Sharmila, R. Kant, Selection of discriminatory gene set for type II diabetes using fisher linear discriminant. *Int J Adv Comput Math Sci.* 5 (2) (2014) 36–42.
- [22] A. Kumar, D.J. Sharmila, Algorithmic approach for removing the redundancy in diabetic gene categories based on semantic similarity and gene expression data. *Interdisciplinary Sciences: Computational Life Sciences* 17 (2015 Mar) 1–7.
- [23] J. Li, A. Mahajan, M.D. Tsai, Ankyrin repeat: a unique motif mediating protein-protein interactions. *Biochemistry* 45 (51) (2006 Dec 26) 15168–15178.
- [24] Y. Liang, F. Zhang, J. Wang, T. Joshi, Y. Wang, D. Xu, Prediction of drought-resistant genes in *Arabidopsis thaliana* using SVM-RFE. *PLoS One* 6 (7) (2011 Jul 15), e21750.
- [25] K. Liu, H.Y. Liu, W. Ye, J.H. Jiang, X. Xu, The initial investigation of the expression of glycosyltransferases in the retina of streptomycin diabetic rats. [Zhonghua Yan Ke Za Zhi] *Chinese Journal of Ophthalmology* 46 (7) (2010 Jul) 580–584.
- [26] M.D. López-Avalos, V.F. Duvivier-Kali, G. Xu, S. Bonner-Weir, A. Sharma, G.C. Weir, Evidence for a role of the ubiquitin-proteasome pathway in pancreatic islets. *Diabetes* 55 (5) (2006 May 1) 1223–1231.
- [27] K. Matrougui, Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase. *Diabetes Metab. Res. Rev.* 26 (1) (2010 Jan 1) 13–16.
- [28] P.J. Miettinen, J. Ustinov, P. Ormio, R. Gao, J. Palgi, E. Hakonen, L. Juntti-Berggren, P.O. Berggren, T. Otonkoski, Downregulation of EGF receptor signaling in pancreatic islets causes diabetes due to impaired postnatal β -cell growth. *Diabetes* 55 (12) (2006 Dec 1) 3299–3308.
- [29] V.K. Mootha, C.M. Lindgren, K.F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstråle, E. Laurila, N. Houstis, PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* 34 (3) (2003 Jul 1) 267–273.
- [30] P.R. Nagib, J. Gameiro, L.G. Stivanin-Silva, M.S. de Arruda, D.M. Villa-Verde, W. Savino, L. Verinaud, Thymic microenvironmental alterations in experimentally induced diabetes. *Immunobiology* 215 (12) (2010 Dec 31) 971–979.
- [31] K.L. Ng, S.K. Mishra, De novo SVM classification of precursor microRNAs from genomic pseudo hairpins using global and intrinsic folding measures. *Bioinformatics* 23 (11) (2007 Jun 1) 1321–1330.
- [32] A.R. Ochman, C.A. Lipinski, J.A. Handler, A.G. Reaume, M.S. Saporito, The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. *J. Pharmacol. Exp. Ther.* 342 (1) (2012 Jul 1) 23–32.
- [33] H. Parikh, E. Carlsson, W.A. Chutkan, L.E. Johansson, H. Storgaard, P. Poulsen, R. Saxena, C. Ladd, P.C. Schulze, M.J. Mazzini, C.B. Jensen, TXNIP regulates peripheral glucose metabolism in humans. *PLoS Med.* 4 (5) (2007 May 1), e158.
- [34] K. Pillwein, M.A. Reardon, H.N. Jayaram, Y. Natsumeda, W.L. Elliott, M.A. Faderan, N. Prajda, W. Sperl, G. Weber, Insulin regulatory effects on purine and pyrimidine metabolism in alloxan diabetic rat liver. *Pediatr. Padol.* 23 (2) (1987 Dec) 135–144.
- [35] J. Qian, G.D. Block, C.S. Colwell, A.V. Matveyenko, Consequences of exposure to light at night on the pancreatic islet circadian clock and function in rats. *Diabetes* 62 (10) (2013 Oct 1) 3469–3478.
- [36] S.B. Rice, G. Nenadic, B.J. Stapley, Mining protein function from text using term-based support vector machines. *BMC Bioinformatics* 6 (1) (2005 May 24) 1.
- [37] A.R. Santiago, J.M. Gaspar, F.I. Baptista, A.J. Cristóvão, P.F. Santos, W. Kamphuis, A.F. Ambrósio, Diabetes changes the levels of ionotropic glutamate receptors in the rat retina. *Mol. Vis.* 15 (2009) 1620–1630.
- [38] C.M. Stapleton, D.G. Mashek, S. Wang, C.A. Nagle, G.W. Cline, P. Thuillier, L.M. Leesnitzer, L.O. Li, J.B. Stimmel, G.I. Shulman, R.A. Coleman, Lysophosphatidic acid activates peroxisome proliferator activated receptor- γ in CHO cells that over-express glycerol 3-phosphate acyltransferase-1. *PLoS One* 6 (4) (2011 Apr 20), e18932.
- [39] S. Van Dieren, J.W. Beulens, A.P. Kengne, L.M. Peelen, G.E. Rutten, M. Woodward, Y.T. Van der Schouw, K.G. Moons, Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. *Heart* 98 (5) (2012 Mar 1) 360–369.
- [40] C. Von Mering, M. Huynen, D. Jaeggi, S. Schmidt, P. Bork, B. Snel, STRING: a database of predicted functional associations between proteins. *Nucleic Acids Res.* 31 (1) (2003 Jan 1) 258–261.
- [41] L. Wassef, D.J. Kelly, R.E. Gilbert, Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. *Kidney Int.* 66 (5) (2004 Nov 1) 1805–1814.
- [42] C. Wilson, Diabetes: pathogenesis of diabetes mellitus: does glutamate have a role? *Nat. Rev. Endocrinol.* 7 (5) (2011 May 1) 248.
- [43] H. Xiao, Z. Gu, G. Wang, T. Zhao, The possible mechanisms underlying the impairment of HIF-1 α pathway signaling in hyperglycemia and the beneficial effects of certain therapies. *Int. J. Med. Sci.* 10 (10) (2013 Jan 1) 1412–1421.
- [44] E. Xu, A. Charbonneau, Y. Rolland, K. Bellmann, L. Pao, K.A. Siminovich, B.G. Neel, N. Beauchemin, A. Marette, Hepatocyte-specific Ptpn6 deletion protects from obesity-linked hepatic insulin resistance. *Diabetes* 61 (8) (2012 Aug 1) 1949–1958.
- [45] M.Z. Zhang, Y. Wang, P. Pauksakon, R.C. Harris, Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. *Diabetes* 63 (6) (2014 Jun 1) 2063–2072.
- [46] R. Zhang, H.Y. Ou, C.T. Zhang, DEG: a database of essential genes. *Nucleic Acids Res.* 32 (Suppl. 1) (2004 Jan 1) D271–D272.
- [47] Y. Izumi, K.A. Yamada, M. Matsukawa, C.F. Zorumski, Effects of insulin on long-term potentiation in hippocampal slices from diabetic rats. *Diabetologia* 46 (7) (2003) 1007–1012.
- [48] W. Zhang, B.J. Thompson, V. Hietakangas, S.M. Cohen, MAPK/ERK signaling regulates insulin sensitivity to control glucose metabolism in *Drosophila*. *PLoS Genetics* 7 (12) (2011), e1002429.